





	ANCN (N=19)	APCN (N=15)	APMCI (N=9)	Overall (N=43)
Sex				
F	12 (63.2%)	14 (93.3%)	3 (33.3%)	29 (67.4%)
M	7 (36.8%)	1 (6.7%)	6 (66.7%)	14 (32.6%)
Age (Years)				
Mean (SD)	70.4 (7.87)	68.2 (5.90)	74.1 (7.23)	70.4 (7.26)
Median [Min, Max]	70.4 [57.0, 83.0]	66.9 [58.1, 79.0]	72.0 [63.4, 83.9]	68.5 [57.0, 83.9]
BMI (lbs/in2)				
Mean (SD)	28.0 (4.06)	27.4 (4.34)	24.3 (3.13)	27.0 (4.16)
Median [Min, Max]	26.8 [22.6, 37.4]	26.5 [19.8, 35.9]	25.2 [18.1, 27.4]	26.5 [18.1, 37.4]

Supplemental Figure I. Demographic characteristics of cohort used in this study.

A**B****C****D**


Supplemental Figure II. Cognitive and amyloid characteristics of cohort used in this study.


FS ROI #	Name
1002	L Caudate/Anterior Cingulate
1003	L caudal middle Frontal
1008	L Parietal Inferior
1010	L Isthmus Cingulate
1012	L Frontal Orbital
1014	L Frontal Orbital
1015	L Middle Temporal
1018	L Frontal Pars Opercularis
1019	L Frontal Pars Opercularis
1020	L Frontal Pars Opercularis
1023	L Post Cingulate
1025	L Precuneus
1026	L Rostral/Anterior Cingulate
1027	L rostral middle Frontal
1028	L Frontal Superior
1029	L Parietal Superior
1030	L Superior Temporal
1031	L Parietal Supramarginal gyrus
1032	L Frontal Orbital
2002	R Caudate/Anterior Cingulate
2003	R caudal middle Frontal
2008	R Parietal Inferior
2010	R Isthmus Cingulate
2012	Right Frontal Orbital
2014	Right Frontal Orbital
2015	R Middle Temporal
2018	R Frontal Pars Opercularis
2019	R Frontal Pars Opercularis
2020	R Frontal Pars Opercularis
2023	R Post Cingulate
2025	R Precuneus
2026	R Rostral/Anterior Cingulate
2027	R rostral middle Frontal
2028	R Frontal Superior
2029	R Parietal Superior
2030	R Superior Temporal
2031	R Parietal Supramarginal gyrus
2032	Right Frontal Orbital

Supplemental Figure III. Brain Regions of Interest Quantitated In Study

<u>Immune Cell Subtype</u>	<u>Parameters</u>
B Cells	CD45 ⁺ CD123 ⁻ CD19 ⁺
Plasma Cells	CD38 ⁺ HLA-DR ⁻
Naïve	CD38 ⁻ HLA-DR ⁺ CD27 ⁻
Memory	CD38 ⁻ HLA-DR ⁺ CD27 ⁺
T Cells	
CD4 ⁺ T Cells	CD45 ⁺ CD123 ⁻ CD19 ⁻ CD3 ⁺ CD4 ⁺ CD8 α ⁻
Activated	CD38 ⁺ HLA-DR ⁺
Effector	CD38 ⁻ HLA-DR ⁻ CD27 ⁻ CD45RA ⁺
Naïve	CD38 ⁻ HLA-DR ⁻ CD27 ⁺ CD45RA ⁺
Memory	CD38 ⁻ HLA-DR ⁻ CD27 ⁺ CD45RA ⁻
CD8 ⁺ T Cells	CD45 ⁺ CD123 ⁻ CD19 ⁻ CD3 ⁺ CD4 ⁻ CD8 α ⁺
Activated	CD38 ⁺ HLA-DR ⁺
Effector	CD38 ⁻ HLA-DR ⁻ CD27 ⁻ CD45RA ⁺
Naïve	CD38 ⁻ HLA-DR ⁻ CD27 ⁺ CD45RA ⁺
Memory	CD38 ⁻ HLA-DR ⁻ CD27 ⁺ CD45RA ⁻
Natural Killer (NK) Cells	CD45 ⁺ CD123 ⁻ CD19 ⁻ CD3 ⁻ CD38 ⁺ CD16 ⁺
Monocytes	
Classical	CD45 ⁺ CD123 ⁻ CD3 ⁻ CD19 ⁻ CD14 ⁺ CD11c ⁺ HLA-DR ⁺
Non-Classical	CD45 ⁺ CD123 ⁻ CD3 ⁻ CD19 ⁻ CD14 ⁻ CD11c ⁺ CD38 ⁻
Dendritic Cells	
Myeloid	CD45 ⁺ CD123 ⁻ CD3 ⁻ CD19 ⁻ CD14 ⁻ CD11c ⁺ CD38 ⁺ HLA-DR ⁺
Plasmacytoid	CD45 ⁺ CD123 ⁺ CD3 ⁻ CD19 ⁻ CD14 ⁻ CD11c ⁻ CD38 ⁺ HLA-DR ⁺


Supplemental Figure IV. Cellular gating strategies. Singlet, viable (FVS-) negative cells were gated as described above into the designated populations.






Supplemental Figure VI. T Cell Phenotype Gating Strategy. Note CD8⁺ T cells use same gates as CD4⁺ subpopulations.

A



B



Supplemental Figure VII. CD4 and CD8 Functional Data For Female Participants.